login
Password reminder
Interventional News
Contact the editor Visit Interventional News Twitter feed Visit Interventional News Facebook page
 

UK’s NICE encourages research on percutaneous venoplasty for multiple sclerosis


Monday, 02 Apr 2012 13:00

Final guidance from the UK’s National Institute for Health and Clinical Excellence (NICE), released on 28 March, encourages further research into percutaneous venoplasty, a procedure which is claimed to relieve symptoms for some people with multiple sclerosis.


The procedure aims to improve blood flow from the brain by using a small inflatable balloon to widen narrowed veins in the neck which carry oxygen-depleted blood. It has been suggested that there could be a link between narrowed veins (called chronic cerebrospinal venous insufficiency, or CCSVI) and the progression of multiple sclerosis.

NICE’s guidance advises the procedure should be only performed on these patients in the context of clinical research. This is so that more evidence on its safety and efficacy can be developed; for example to explore the impact that the procedure could have on quality of life in the long term.

Professor Bruce Campbell, chair of the independent committee that develops NICE’s interventional procedures guidance said: “Multiple sclerosis can be a distressing and disabling condition with a lack of effective treatments. This means that it is really important to find out whether percutaneous venoplasty is clinically effective and safe for use in the NHS. Based on the existing evidence, we believe that clinicians should only consider offering percutaneous venoplasty as a treatment option for people with multiple sclerosis who fit the diagnostic criteria for CCSVI, as part of structured clinical trials”


“This is so that we can learn more about whether venoplasty works and if so for how long. Further research could also investigate the relationship between MS and CCSVI, as this is very unclear at present”.

NICE’s guidance outlines what NHS healthcare professionals should do if they wish to consider percutaneous venoplasty as a treatment option, based on its safety and efficacy only. Cost is not considered in this type of guidance.




Add New Comment

Related Items


Most popular


Cyanoacrylate embolisation agent non-inferior to radiofrequency ablation for incompetent great saphenous veins treatment
Friday, 03 Jul 2015
Twelve-month results from the VeClose trial have demonstrated cyanoacrylate adhesive (CAE) is non-inferior to radiofrequency ablation (RFA) for the treatment of incompetent great saphenous veins. Cyanoacrylate embolisation agent non-inferior to radiofrequency ablation for incompetent great saphenous veins treatment

Biolas introduces VariClose in Europe
Thursday, 16 Jul 2015
After the European launch in April 2015, Biolas has introduced the VariClose Vein Sealing Systems in the European market for the treatment of varicose veins. Biolas introduces VariClose in Europe

Lombard Medical acquires EVAR stent graft developer Altura Medical
Friday, 31 Jul 2015
Altura Medical has developed an ultra-low profile endovascular stent graft technology that, according to Lombard, offers a simple and predictable solution for the treatment of standard abdominal ... Lombard Medical acquires EVAR stent graft developer Altura Medical

Features


Patient selection is key for SIRT with first-line chemotherapy
Tuesday, 18 Aug 2015
Ricky Sharma, professor and honorary consultant of Clinical Oncology at the University of Oxford and Oxford University Hospitals Trust tells Interventional News: “We need to know more about patient ... Patient selection is key for SIRT with first-line chemotherapy

Choosing horses for courses: Using liquid agents to embolize endoleaks
Monday, 27 Jul 2015
Robert Morgan, vascular interventional radiologist, St Georges Hospital, London, UK, tells Interventional News why he uses liquid embolic agents, such as ethylene vinyl oxide copolymer (EVOH-based) ... Choosing horses for courses: Using liquid agents to embolize endoleaks

Profiles


Lindsay Machan
Thursday, 28 May 2015
“Focusing on maximising rewards has sidelined more ideas than it has helped individual inventors. S... Lindsay Machan

Gao-Jun Teng
Thursday, 11 Dec 2014
In the future, will interventional radiology be a subspecialty of radiology, or surgery? asks Gao-J... Gao-Jun Teng

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions